Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy
Objective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by 1H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/8454751 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548499452854272 |
|---|---|
| author | Fan Ping Xuan Wang Jing Yang Mei-cen Zhou Wei Li Ling-ling Xu Yu-xiu Li |
| author_facet | Fan Ping Xuan Wang Jing Yang Mei-cen Zhou Wei Li Ling-ling Xu Yu-xiu Li |
| author_sort | Fan Ping |
| collection | DOAJ |
| description | Objective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by 1H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipid (IHCL) level of nonalcoholic fatty liver disease (NAFLD). Methods. 40 NAFLD patients meeting inclusion and exclusion criteria with metabolic syndrome (MS) but without overt diabetes mellitus will be included. Patients will be randomized to 52-week treatment with either rosuvastatin (10 mg/d) or blank control. The primary end point is IHCL evaluated by 1H-MRS, which was considered to be the most accurate noninvasive method for the evaluation of NAFLD. Secondary end points include homeostasis model assessment of insulin resistance (HOMA-IR) index on behalf of insulin resistance level and lipid parameters. Safety indicators will be monitored such as liver function, renal function, muscle stability, and glucose metabolism. The aims of the present study are noteworthy in respect that (1) IHCL is a quantitative indicator for evaluating the degree of fatty liver disease and 1H-MRS is a noninvasive technique to provide this specific index precisely, (2) meanwhile the HOMA-IR index and lipid parameters will be monitored, and (3) the safety of rosuvastatin treatment for 52 weeks will be evaluated including glucose metabolism, muscle stability, liver function, and renal function. |
| format | Article |
| id | doaj-art-e555c68ad9bb41939a471a20b85eec43 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-e555c68ad9bb41939a471a20b85eec432025-02-03T06:13:58ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/84547518454751Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance SpectroscopyFan Ping0Xuan Wang1Jing Yang2Mei-cen Zhou3Wei Li4Ling-ling Xu5Yu-xiu Li6Department of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaDepartment of Radiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaDepartment of Endocrinology, Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ministry of Health, Beijing, ChinaObjective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by 1H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipid (IHCL) level of nonalcoholic fatty liver disease (NAFLD). Methods. 40 NAFLD patients meeting inclusion and exclusion criteria with metabolic syndrome (MS) but without overt diabetes mellitus will be included. Patients will be randomized to 52-week treatment with either rosuvastatin (10 mg/d) or blank control. The primary end point is IHCL evaluated by 1H-MRS, which was considered to be the most accurate noninvasive method for the evaluation of NAFLD. Secondary end points include homeostasis model assessment of insulin resistance (HOMA-IR) index on behalf of insulin resistance level and lipid parameters. Safety indicators will be monitored such as liver function, renal function, muscle stability, and glucose metabolism. The aims of the present study are noteworthy in respect that (1) IHCL is a quantitative indicator for evaluating the degree of fatty liver disease and 1H-MRS is a noninvasive technique to provide this specific index precisely, (2) meanwhile the HOMA-IR index and lipid parameters will be monitored, and (3) the safety of rosuvastatin treatment for 52 weeks will be evaluated including glucose metabolism, muscle stability, liver function, and renal function.http://dx.doi.org/10.1155/2016/8454751 |
| spellingShingle | Fan Ping Xuan Wang Jing Yang Mei-cen Zhou Wei Li Ling-ling Xu Yu-xiu Li Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy International Journal of Endocrinology |
| title | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy |
| title_full | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy |
| title_fullStr | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy |
| title_full_unstemmed | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy |
| title_short | Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy |
| title_sort | rationale and design of rnafh study effect of rosuvastatin 10 mg d on nonalcoholic fatty liver in metabolic syndrome patients without overt diabetes evaluated by 1h magnetic resonance spectroscopy |
| url | http://dx.doi.org/10.1155/2016/8454751 |
| work_keys_str_mv | AT fanping rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT xuanwang rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT jingyang rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT meicenzhou rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT weili rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT linglingxu rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy AT yuxiuli rationaleanddesignofrnafhstudyeffectofrosuvastatin10mgdonnonalcoholicfattyliverinmetabolicsyndromepatientswithoutovertdiabetesevaluatedby1hmagneticresonancespectroscopy |